Nortriptylin Glenmark (Nortriptyline)

Nortriptyline acts on monoamine neurotransmitter pathways and is indicated for several psychiatric and neurological conditions.

• Major depressive disorder: alleviates depressive symptoms and improves mood in adult patients.
• Chronic neuropathic pain: reduces pain intensity associated with peripheral neuropathy.
• Migraine prophylaxis: decreases frequency and severity of migraine attacks.
• Anxiety disorders: helps manage anxiety symptoms when other agents are insufficient.
• Sleep disturbances: improves sleep quality secondary to depressive symptoms.

• Nortriptyline inhibits the reuptake of norepinephrine and serotonin by blocking their neuronal transporters, leading to increased concentrations of these neurotransmitters in the synaptic cleft. The elevated norepinephrine enhances adrenergic signaling, while higher serotonin levels modulate mood, anxiety and pain pathways. Additionally, the drug exhibits antagonistic activity at muscarinic, histamine H1 and alpha‑adrenergic receptors, contributing to its therapeutic and side‑effect profile.

Nortriptyline may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dry mouth
• Constipation
• Drowsiness
• Weight gain

Serious or Rare Side Effects

• Cardiac arrhythmias or conduction disturbances
• Seizures
• Serotonin syndrome

When prescribing nortriptyline, several safety considerations should be observed.

• Cardiac assessment: evaluate history of heart disease before initiating therapy.
• Suicidal monitoring: observe for emergence of suicidal thoughts, especially in early treatment.
• Elderly caution: start with low dose and monitor for anticholinergic effects.
• Discontinuation: taper gradually to avoid withdrawal symptoms.
• Hepatic impairment: adjust dose in patients with liver dysfunction.
• Store at below 25°C: keep in original packaging, protect from moisture and light.

Nortriptyline can interact with a variety of medicines; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of severe hypertensive crisis or serotonin syndrome.
• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): may precipitate serotonin syndrome.
• Antiarrhythmic agents (e.g., quinidine, flecainide): can enhance cardiotoxic effects.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase nortriptyline plasma levels.
• CNS depressants (e.g., alcohol, benzodiazepines): may augment sedation and respiratory depression.